84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]陳斯亮,石瑛,湯辰明,等.基于16S核糖體RNA測(cè)序研究健脾方對(duì)絕經(jīng)后骨質(zhì)疏松癥小鼠腸道菌群的影響[J].中醫(yī)正骨,2023,35(06):11-17,23.
　CHEN Siliang,SHI Ying,TANG Chenming,et al.A study of the effects of Jianpi Fang(健脾方)on intestinal flora of mice with postmenopausal osteoporosis based on 16S ribosomal RNA gene sequencing[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(06):11-17,23.
點(diǎn)擊復(fù)制

基于16S核糖體RNA測(cè)序研究健脾方對(duì)絕經(jīng)后骨質(zhì)疏松癥小鼠腸道菌群的影響()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第35卷
期數(shù):
2023年06期
頁碼:
11-17,23
欄目:
基礎(chǔ)研究
出版日期:
2023-06-20

文章信息/Info

Title:
A study of the effects of Jianpi Fang(健脾方)on intestinal flora of mice with postmenopausal osteoporosis based on 16S ribosomal RNA gene sequencing
作者:
陳斯亮; 石瑛; 湯辰明; 馬威; 詹紅生
(上海中醫(yī)藥大學(xué)附屬曙光醫(yī)院,上海 201203)
Author(s):
CHEN Siliang; SHI Ying; TANG Chenming; MA Wei; ZHAN Hongsheng
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China
關(guān)鍵詞:
骨質(zhì)疏松; 絕經(jīng)后;  胃腸道微生物群;  RNA; 核糖體; 16S;  健脾方
Keywords:
osteoporosis; postmenopausal;  gastrointestinal microbiome;  RNA; Ribosomal; 16S;  Jianpi fang
摘要:
目的:探討健脾方對(duì)絕經(jīng)后骨質(zhì)疏松癥(osteoporosis,OP)小鼠腸道菌群的影響。方法:將30只雌性C57BL/6小鼠隨機(jī)分為假手術(shù)組、模型組和健脾方組,每組10只。模型組和健脾方組小鼠通過雙側(cè)卵巢摘除術(shù)進(jìn)行OP造模,假手術(shù)組小鼠打開腹腔后切除卵巢附近的一團(tuán)脂肪組織,保留卵巢。造模后第7天,假手術(shù)組和模型組小鼠以生理鹽水灌胃,健脾方組以健脾方藥液灌胃(中藥配方顆粒用量為54 mg·kg-1),3組小鼠均每天灌胃1次,每次0.2 mL,連續(xù)灌胃28 d。藥物干預(yù)結(jié)束后,測(cè)定小鼠體質(zhì)量,獲取各組小鼠糞便樣本、左側(cè)股骨,切取子宮并稱重,進(jìn)行小鼠腸道菌群16S核糖體RNA測(cè)序分析及小鼠股骨病理學(xué)觀察。結(jié)果:①一般情況。實(shí)驗(yàn)期間各組均無小鼠死亡。藥物干預(yù)前,3組小鼠體質(zhì)量的差異無統(tǒng)計(jì)學(xué)意義[(20.88±0.83)g,(20.65±0.74)g,(20.59±0.47)g,F=0.484,P=0.622]。藥物干預(yù)結(jié)束后,模型組小鼠的體質(zhì)量高于假手術(shù)組和健脾方組[(26.96±1.63)g,(23.42±0.84)g,P=0.000;(26.96±1.63)g,(24.62±1.55)g,P=0.001],假手術(shù)組和健脾方組小鼠體質(zhì)量的差異無統(tǒng)計(jì)學(xué)意義(P=0.063)。假手術(shù)組小鼠的子宮質(zhì)量高于模型組和健脾方組[(0.66±0.05)g,(0.24±0.05)g,P=0.000;(0.66±0.05)g,(0.28±0.06)g,P=0.000],模型組和健脾方組小鼠子宮質(zhì)量的差異無統(tǒng)計(jì)學(xué)意義(P=0.053)。②小鼠腸道菌群豐度分析結(jié)果。假手術(shù)組與模型組含有499個(gè)共同操作分類單元(operational taxonomic units,OTUs)數(shù)據(jù); 除共同OTUs數(shù)據(jù)外,假手術(shù)組有87個(gè)特異性O(shè)TUs數(shù)據(jù),模型組有74個(gè)特異性O(shè)TUs數(shù)據(jù)。模型組與健脾方組含有489個(gè)共同OTUs數(shù)據(jù); 除共同OTUs數(shù)據(jù)外,模型組有84個(gè)特異性O(shè)TUs數(shù)據(jù),健脾方組有54個(gè)特異性O(shè)TUs數(shù)據(jù)。偏最小二乘法判別分析結(jié)果顯示,3組小鼠腸道菌群豐度差異明顯。③小鼠腸道菌群結(jié)構(gòu)分析結(jié)果。物種累計(jì)曲線隨樣本量增加逐漸趨于平緩,說明樣品中的物種已經(jīng)基本被測(cè)序覆蓋,測(cè)序數(shù)據(jù)量充足。3組小鼠腸道菌群相對(duì)豐度在門水平處于前4位的依次為擬桿菌門、厚壁菌門、放線菌門、脫硫菌門,相對(duì)豐度在屬水平處于前5位的依次為Muri菌屬、乳桿菌屬、擬普雷沃菌屬、梭菌屬、糞桿菌屬。3組小鼠厚壁菌門、脫硫菌門相對(duì)豐度比較,總體差異均無統(tǒng)計(jì)學(xué)意義。假手術(shù)組和健脾方組擬桿菌門相對(duì)豐度均高于模型組(23.19±2.09,17.12±3.87,P=0.016; 23.58±2.46,17.12±3.87,P=0.012)、放線菌門相對(duì)豐度低于模型組(0.32±0.29,0.79±0.31,P=0.027; 0.26±0.07,0.79±0.31,P=0.014); 其余各組間兩兩比較,組間差異均無統(tǒng)計(jì)學(xué)意義。3組小鼠Muri菌屬、乳桿菌屬、糞桿菌屬相對(duì)豐度比較,總體差異均無統(tǒng)計(jì)學(xué)意義。假手術(shù)組擬普雷沃菌屬相對(duì)豐度高于模型組(4.96±1.77,1.33±0.37,P=0.009)、梭菌屬相對(duì)豐度低于模型組(0.45±0.17,1.41±0.18,P=0.000),健脾方組梭菌屬相對(duì)豐度低于模型組(0.62±0.30,1.41±0.18,P=0.001); 其余各組間兩兩比較,組間差異均無統(tǒng)計(jì)學(xué)意義。④健脾方組與模型組差異菌群KEGG分析結(jié)果。健脾方組與模型組有明顯差異的代謝途徑有維生素B6代謝、硫化物代謝、硒化物代謝、硫氨基酸代謝、硫胺素代謝、鈣離子通道。⑤小鼠股骨病理學(xué)觀察結(jié)果。模型組小鼠的骨小梁厚度、骨小梁數(shù)量均低于假手術(shù)組[(50.13±7.72)mm,(71.87±6.20)mm,P=0.000;(1.87±0.92)個(gè)·mm-1,(4.40±1.24)個(gè)·mm-1,P=0.000],骨小梁分離度高于假手術(shù)組[(344.60±41.32)mm,(205.80±27.21)mm,P=0.000]。健脾方組小鼠的骨小梁厚度、骨小梁數(shù)量均低于假手術(shù)組[(60.53±6.38)mm,(71.87±6.20)mm,P=0.000;(3.13±0.92)個(gè)·mm-1,(4.40±1.24)個(gè)·mm-1,P=0.002],健脾方組與假手術(shù)組小鼠骨小梁分離度的差異無統(tǒng)計(jì)學(xué)意義。健脾方組小鼠的骨小梁厚度、骨小梁數(shù)量均高于模型組[(60.53±6.38)mm,(50.13±7.72)mm,P=0.000;(3.13±0.92)個(gè)·mm-1,(1.87±0.92)個(gè)·mm-1,P=0.002],骨小梁分離度低于模型組[(221.40±33.16)mm,(344.60±41.32)mm,P=0.000]。結(jié)論:健脾方能夠調(diào)節(jié)絕經(jīng)后OP小鼠腸道菌群結(jié)構(gòu),改變代謝途徑,這可能是其治療OP的作用機(jī)制之一。
Abstract:
Objective:To explore the effects of Jianpi Fang(健脾方,JPF)on intestinal flora of postmenopausal osteoporosis(PMOP)mice.Methods:Thirty female C57BL/6 mice were randomly divided into sham-operated group,model group and JPF group,10 mice in each group.The mice in model group and JPF group were subjected to bilateral ovariectomy for inducing PMOP; while the ones in sham-operated group underwent removal of peri-ovarian adipose tissues,with ovaries retained.On the 7th day after the modeling operation,the mice in sham-operated group and model group were intragastric administrated with normal saline,while the ones in JPF group with JPF decoction(the dosage of Chinese medicinal granules was 54 mg/kg).All mice in the 3 groups were intragastric administrated once a day,0.2 mL at a time for consecutive 28 days.After the end of drug intervention,the body mass of the mice was measured and their stool samples and left femurs were harvested,moreover their uteri were dissected and weighed,and analysis on 16S ribosomal RNA(rRNA)gene sequencing of intestinal flora and pathological observation on femurs of the mice were conducted.Results:①No dead mice were found during the experiment period.There was no statistical difference in body mass among the 3 groups before the drug intervention(20.88±0.83,20.65±0.74,20.59±0.47 g,F=0.484,P=0.622).After the end of drug intervention,the body mass was higher in model group compared with that of sham-operated group and JPF group(26.96±1.63 vs 23.42±0.84 g,P=0.000; 26.96±1.63 vs 24.62±1.55 g,P=0.001),while the difference in body mass between sham-operated group and JPF group was not statistically significant(P=0.063).The quality of uteri was higher in sham-operated group compared with that of model group and JPF group(0.66±0.05 vs 0.24±0.05 g,P=0.000; 0.66±0.05 vs 0.28±0.06 g,P=0.000),while there was no significant difference between model group and JPF group(P=0.053).②The sham-operated group and model group shared 499 common operational taxonomic units(OTUs).In addition to the common OTUs,87 specific OTUs were found in sham-operated group,and 74 ones were observed in model group.The model group and the JPF group shared 489 common OTUs.In addition to the common OTUs,84 specific OTUs were found in model group,and 54 ones were observed in JPF group.The results of partial least squares discriminant analysis(PLS-DA)showed that there were significant differences in the abundance of intestinal flora among the 3 groups.③The species accumulation curve gradually flattened out with the sample size increased,indicating that the species in the samples had been adequately covered by sequencing and the sequencing data were sufficient.At the phylum level,the top 4 abundant phyla in the mouse intestinal flora of the 3 groups were Bacteroidetes,Firmicutes,Actinobacteria and Desulfobacterota in turn; while,at the genus level,the top 5 abundant genera were Muri,Lactobacillus,Alloprevotella,Clostridium and Faecalibacterium in turn.There was no significant differences in the relative abundance of Firmicutes and Desulfobacterota among the 3 groups.The relative abundance of Bacteroidetes was higher,while the relative abundance of Actinobacteria was lower in sham-operated group and JPF group compared to model group(23.19±2.09 vs 17.12±3.87,P=0.016; 23.58±2.46 vs 17.12±3.87,P=0.012; 0.32±0.29 vs 0.79±0.31,P=0.027; 0.26±0.07 vs 0.79±0.31,P=0.014).Further pairwise comparison showed that there was no statistical difference in the relative abundance of Bacteroidetes and Actinobacteria between sham-operated group and JPF group.There was no significant differences in the relative abundance of Muri,Lactobacillus and Faecalibacterium among the 3 groups.The relative abundance of Alloprevotella was higher in sham-operated group compared to model group(4.96±1.77 vs 1.33±0.37,P=0.009),and the relative abundance of Clostridium was lower in sham-operated group and JPF group compared to model group(0.45±0.17 vs 1.41±0.18,P=0.000; 0.62±0.30 vs 1.41±0.18,P=0.001).Further pairwise comparison showed that there was no statistical difference in the relative abundance of Alloprevotella between sham-operated group and JPF group as well as between model group and JPF group,and no statistical difference in the relative abundance of Clostridium between sham-operated group and JPF group.④The significant differences in metabolic pathways,including vitamin B6 metabolism,sulfide metabolism,selenocompound metabolism,sulfur amino acid metabolism,thiamine metabolism and calcium ion channels,were found between JPF group and model group.⑤The trabecular thickness(Tb.Th)and trabecular number(Tb.N)in femurs were less,while the trabecular separation(Tb.Sp)was higher in model group compared to sham-operated group(50.13±7.72 vs 71.87±6.20 mm,P=0.000; 1.87±0.92 vs 4.40±1.24 trabeculae/mm,P=0.000; 344.60±41.32 vs 205.80±27.21 mm,P=0.000).The Tb.Th and Tb.N in femurs were less in JPF group compared to sham-operated group(60.53±6.38 vs 71.87±6.20 mm,P=0.000; 3.13±0.92 vs 4.40±1.24 trabeculae/mm,P=0.002),while there was no significant differences in Tb.Sp between JPF group and sham-operated group.The Tb.Th was greater,the Tb.N was more,while the Tb.Sp was lower in JPF group compared to model group(60.53±6.38 vs 50.13±7.72 mm,P=0.000; 3.13±0.92 vs 1.87±0.92 trabeculae/mm,P=0.002; 221.40±33.16 vs 344.60±41.32 mm,P=0.000).Conclusion:The JPF can modulate the intestinal flora structure and alter the metabolic pathways in PMOP mice,which may be one of its mechanisms of action in treatment of OP.

參考文獻(xiàn)/References:

[1] 中華中醫(yī)藥學(xué)會(huì).骨質(zhì)疏松性骨折中醫(yī)診療指南[J].中醫(yī)正骨,2023,35(1):1-9.
[2] SHETH T,PITCHUMONI C S,DAS K M.Musculoskeletal manifestations in inflammatory bowel disease:a revisit in search of immunopathophysiological mechanisms[J].J Clin Gastroenterol,2014,48(4):308-317.
[3] MA S,QIN J,HAO Y,et al.Association of gut microbiota composition and function with an aged rat model of senile osteoporosis using 16S rRNA and metagenomic sequencing analysis[J].Aging(Albany NY),2020,12(11):10795-10808.
[4] SEELY K D,KOTELKO C A,DOUGLAS H,et al.The human gut microbiota:a key mediator of osteoporosis and osteogenesis[J].Int J Mol Sci,2021,22(17):9452.
[5] 張洪源,任廣振,黃建政,等.健脾類中藥多糖對(duì)脾虛相關(guān)病癥腸道菌群影響研究現(xiàn)狀[J].中國中醫(yī)藥信息雜志,2022,29(2):147-151.
[6] 唐亨方,姚嘯生,戚曉楠.補(bǔ)腎健脾類中藥改善腸道菌群治療骨質(zhì)疏松癥的機(jī)制分析[J].實(shí)用中醫(yī)內(nèi)科雜志,2021,35(3):1-4.
[7] 王立童,趙詠芳,王翔,等.密骨膠囊和健脾方對(duì)去卵巢大鼠骨結(jié)構(gòu)和力學(xué)性能的影響[J].中國骨質(zhì)疏松雜志,2009,15(1):27-31.
[8] 葛月賓,王麗君.小鼠去卵巢骨質(zhì)疏松模型的建立及OPG/RANKL的表達(dá)[J].中國中醫(yī)骨傷科雜志,2008,16(12):33-35.
[9] 盧林,楊景云,李丹紅.脾虛濕盛泄瀉患者腸道微生態(tài)及舌部菌群變化的臨床觀察[J].中國微生態(tài)學(xué)雜志,2007,19(4):333-334.
[10] MCCABE L,BRITTON R A,PARAMESWARAN N.Prebiotic and probiotic regulation of bone health:role of the intestine and its microbiome[J].Curr Osteoporos Rep,2015,13(6):363-371.
[11] CLAESSON M J,CUSACK S,O'SULLIVAN O,et al.Composition,variability,and temporal stability of the intestinal microbiota of the elderly[J].Proc Natl Acad Sci U S A,2011,108(Suppl 1):4586-4591.
[12] 葛臻,丁閱異.骨質(zhì)疏松癥的中醫(yī)證素分布研究[J].湖南中醫(yī)雜志,2019,35(9):126-127.
[13] 黃文武,彭穎,王夢(mèng)月,等.四君子湯及其單味藥水煎液對(duì)脾虛大鼠腸道菌群的調(diào)節(jié)作用[J].中國實(shí)驗(yàn)方劑學(xué)雜志,2019,25(11):8-15.
[14] 王立童,趙詠芳,王翔,等.具有補(bǔ)腎、健脾功效的中藥復(fù)方對(duì)切卵大鼠腎臟、股骨中VDRmRNA表達(dá)的影響[J].中國中醫(yī)骨傷科雜志,2009,17(4):4-7.
[15] ADAK A,KHAN M R.An insight into gut microbiota and its functionalities[J].Cell Mol Life Sci,2019,76(3):473-493.
[16] LIN H,HUANG Y,TIAN T,et al.Propionate promotes vitamin D receptor expression via yes-associated protein in rats with short bowel syndrome[J].Biochem Biophys Res Commun,2020,523(3):645-650.
[17] FATAHI-BAFGHI M.Antibiotic resistance genes in the actinobacteria phylum[J].Eur J Clin Microbiol Infect Dis,2019,38(9):1599-1624.
[18] DI D S,LI C,DAI Y,et al.Integrative analysis of LGR5/6 gene variants,gut microbiota composition and osteoporosis risk in elderly population[J].Front Microbiol,2021,12:765008.
[19] ZHANG Y W,CAO M M,LI Y J,et al.The preventive effects of probiotic prevotella histicola on the bone loss of mice with ovariectomy-mediated osteoporosis[J].Microorganisms,2023,11(4):950.
[20] OBI Y,MIKAMI S,HAMANO T,et al.Intravenous vitamin B6 increases resistance to erythropoiesis-stimulating agents in hemodialysis patients:a randomized controlled trial[J].J Ren Nutr,2016,26(6):380-390.
[21] YOUNG R C,BLASS J P.Iatrogenic nutritional deficien-cies[J].Annu Rev Nutr,1982,2:201-227.
[22] DARLING A L,MILLWARD D J,LANHAM-NEW S A.Dietary protein and bone health:towards a synthesised view[J].Proc Nutr Soc,2021,80(2):165-172.
[23] ANDREEV D,LIU M,WEIDNER D,et al.Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin[J].J Clin Invest,2020,130(9):4811-4830.

相似文獻(xiàn)/References:

[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學(xué)朋,朱立國.骨疏康膠囊對(duì)去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):12.
[3]陳冠軍,陳揚(yáng),莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對(duì)絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(06):19.
[6]項(xiàng)旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(06):20.
[7]史曉林,李春雯,張志強(qiáng).弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時(shí)間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機(jī)制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(06):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(06):3.
[11]韓艷,溫利平,劉娜,等.補(bǔ)腎活血方對(duì)去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):7.
[12]歐國峰,劉鑫,董博,等.絕經(jīng)后骨質(zhì)疏松癥的免疫學(xué)研究進(jìn)展[J].中醫(yī)正骨,2016,28(08):70.
[13]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(06):1.
[14]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質(zhì)疏松癥腎虛證的關(guān)系[J].中醫(yī)正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質(zhì)疏松大鼠骨代謝紊亂的作用機(jī)制研究[J].中醫(yī)正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(06):1.
[16]劉晨,李興勇,姚興璋,等.絕經(jīng)后骨質(zhì)疏松癥的流行病學(xué)概況及發(fā)病機(jī)制研究進(jìn)展[J].中醫(yī)正骨,2018,30(03):52.
[17]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動(dòng)物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質(zhì)疏松癥發(fā)生發(fā)展過程中細(xì)胞自噬的機(jī)制[J].中醫(yī)正骨,2018,30(04):59.
[18]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(06):20.
[19]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ) 治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(06):11.
[20]趙凡,劉全,吳連國.口服強(qiáng)骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強(qiáng)骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(06):26.

備注/Memo

備注/Memo:
基金項(xiàng)目:國家自然科學(xué)基金項(xiàng)目(81674003); “華東片區(qū)及市級(jí)中醫(yī)專科筋骨病損專科聯(lián)盟建設(shè)”項(xiàng)目 通訊作者:石瑛 E-mail:[email protected]
更新日期/Last Update: 1900-01-01